Market Currents
Rigel Pharmaceuticals (RIGL +3.2%) signs an agreement to develop its R256 asthma drug with...
-
Tuesday, June 19, 2012, 11:16 AM ETRigel Pharmaceuticals (RIGL +3.2%) signs an agreement to develop its R256 asthma drug with AstraZeneca (AZN +3%) in a deal that could be worth $100M plus royalties if the treatment ever reaches market. There's still a long way to go, as R256 is yet to be tested on humans. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
